ASX:LDX Lumos Diagnostics (LDX) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free LDX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Lumos Diagnostics alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Lumos DiagnosticsLumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.Read More Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here LDX Stock News HeadlinesApril 11, 2024 | proactiveinvestors.comLumos Diagnostics’ breakthroughs in paediatric care with FebriDxJanuary 30, 2024 | msn.comASX Health Stocks: NSB jumps 11pc after quarterly update; Lumos makes great strides with FDAApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. November 11, 2023 | investing.comLumos Diagnostics Holdings Ltd (LDX)September 10, 2023 | finance.yahoo.comLumos Diagnostics Holdings Limited (LDX.AX)September 1, 2023 | finance.yahoo.comLumos Diagnostics Holdings Full Year 2023 Earnings: US$0.038 loss per share (vs US$0.30 loss in FY 2022)August 23, 2023 | wsj.comLumos Diagnostics Holdings Ltd.August 18, 2023 | finance.yahoo.comLumos Receives US FDA Clearance for FebriDx®April 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. February 15, 2022 | finance.yahoo.comLiverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community PharmaciesSee More Headlines Receive LDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:LDX CUSIPN/A CIKN/A Weblumosdiagnostics.com Phone61 3 9692 7222FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,820,000.00 Net Margins-107.38% Pretax MarginN/A Return on Equity-87.62% Return on Assets-26.13% Debt Debt-to-Equity Ratio92.41 Current Ratio0.69 Quick Ratio0.77 Sales & Book Value Annual Sales$8.21 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares481,300,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Samuel LanyonExecutive ChairmanMr. Douglas WardCEO, MD & DirectorMr. Barrie LambertChief Financial OfficerDr. Sacha Dopheide Ph.D.Chief Technology OfficerMs. Jennifer ChristiansenVice President of Corporate Marketing & CommunicationsMs. Sarah GlubkaSenior Director of Human ResourcesMr. Paul KaseSenior Vice President of Commercial OperationsMs. Tracy Weimar BAMBA, Company SecretaryMore ExecutivesKey CompetitorsANGLEOTCMKTS:ANPCYAustralian Clinical LabsASX:ACLBARD1 Life SciencesASX:BD1BCAL DiagnosticsASX:BDXbioAffinity TechnologiesNASDAQ:BIAFWView All CompetitorsInsidersDoug WardBought 250,000 shares on 10/18/2023Total: $21,750.00 ($0.09/share)Catherine RobsonSold 428,571 sharesTotal: $29,999.97 ($0.07/share) This page (ASX:LDX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Diagnostics Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
